Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2009 1
2011 1
2014 3
2016 1
2017 4
2018 3
2019 2
2020 5
2021 3
2022 3
2023 3
2024 2
2025 4
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Harding JJ, et al. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. Lancet Oncol. 2023. PMID: 37276871 Clinical Trial.
Infigratinib for cholangiocarcinoma.
Sadeghi S. Sadeghi S. Drugs Today (Barc). 2022 Jul;58(7):327-334. doi: 10.1358/dot.2022.58.7.3408813. Drugs Today (Barc). 2022. PMID: 35851868 Review.
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells.
Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu Y, Kramer A, Wilson M, Zhou K, Dunn ZS, Fang Y, Yu J, Kim YJ, Huang J, Shen X, Wang YC, Hon R, Basso T, Chen E, Zhu E, Lin S, Neal A, Moatamed NA, Oh SS, Sadeghi S, Pan C, Wang A, Lusis AJ, Zhou XJ, Zhou JJ, Pellegrini M, Wang P, Memarzadeh S, Yang L. Li YR, et al. Among authors: sadeghi s. Med. 2025 Oct 10;6(10):100804. doi: 10.1016/j.medj.2025.100804. Epub 2025 Aug 12. Med. 2025. PMID: 40803321 Free article.
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ; HERIZON-BTC-01 Study Group. Pant S, et al. JAMA Oncol. 2026 Jan 1;12(1):106-109. doi: 10.1001/jamaoncol.2025.4736. JAMA Oncol. 2026. PMID: 41264278 Free PMC article.
HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Noureddin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. Sun N, et al. Among authors: sadeghi s. Hepatology. 2023 Mar 1;77(3):774-788. doi: 10.1002/hep.32692. Epub 2023 Feb 17. Hepatology. 2023. PMID: 35908246 Free PMC article.
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Javle M, et al. Among authors: sadeghi s. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. doi: 10.1016/S2468-1253(21)00196-5. Epub 2021 Aug 3. Lancet Gastroenterol Hepatol. 2021. PMID: 34358484 Clinical Trial.
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.
Zhao C, Lee YT, Melehy A, Kim M, Yang JZ, Zhang C, Kim J, Zhang RY, Lee J, Kim H, Ju Y, Tsai YJ, Zhou XJ, Han SB, Sadeghi S, Finn RS, Saab S, Lu DS, Chiang J, Park JH, Brennan TV, Wisel SA, Alsudaney M, Kuo A, Ayoub WS, Kim H, Trivedi HD, Wang Y, Vipani A, Kim IK, Todo T, Steggerda JA, Voidonikolas G, Kosari K, Nissen NN, Saouaf R, Singal AG, Sim MS, Elashoff DA, You S, Agopian VG, Yang JD, Tseng HR, Zhu Y. Zhao C, et al. Among authors: sadeghi s. J Exp Clin Cancer Res. 2025 May 1;44(1):136. doi: 10.1186/s13046-025-03379-7. J Exp Clin Cancer Res. 2025. PMID: 40307890 Free PMC article.
Systemic therapy for cholangiocarcinoma.
Sadeghi S, Finn RS. Sadeghi S, et al. Clin Liver Dis (Hoboken). 2014 Apr 28;3(4):86-89. doi: 10.1002/cld.337. eCollection 2014 Apr. Clin Liver Dis (Hoboken). 2014. PMID: 30992893 Free PMC article. Review. No abstract available.
37 results